EV/EBITDA Multiple: vTv Therapeutics, Inc. (VTVT)

Corporate company logo of vtvtherapeutics.com (VTVT)

vTv Therapeutics Inc. (VTVT) generates revenue based on bringing metabolism therapies to market, including the drug TTP399 and developments targeting psoriasis. This chart on GURU.Markets confirms this, recording the metric at 0.00. An innovative glucose regulation method allows the company to maintain pricing power. However, the platform's success depends on the FDA's verdict, and patent protection has not yet created a sustainable cash flow.

VTVT (vTv Therapeutics) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/17/2026

vTv Therapeutics, Inc. (VTVT) - metric breakdowns and financial figures

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Initial company analysis:VTVT (vtvtherapeutics.com)
Product sample of vTv Therapeutics

EV/EBITDA assesses the business value relative to its operating profit before depreciation, taxes, and interest, allowing for the determination of the real value of assets without the influence of debt load. By analyzing the EV/EBITDA level over a time interval, an investor identifies the undervaluation of vTv Therapeutics Inc. (VTVT), given that the current market confidence is based on expectations regarding the update of clinical programs and the effectiveness of new management.

Who vTv Therapeutics Inc. competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ascendispharma.com ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics Corp - EV/EBITDA Multiple|Company Value to EBITDA Rhythm Pharmaceuticals Inc|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Pharmaceuticals|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (Soleno Therapeutics Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization amicusrx.com FOLD|89bio Pharma (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Corp|Enterprise Value to EBITDA Ratio MBX Corp (MBX)|EV/EBITDA Multiple ALT|Enterprise Value to EBITDA Ratio Aardvark Therapeutics Inc AARD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sagimet Biosciences, Inc. SGMT|BioAge - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Biomea Fusion Corp - EV/EBITDA Multiple|QNCX - EV/EBITDA Multiple|GUTS: EV/EBITDA Multiple|Agape ATP Corp. (ATPC) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization pluri-biotech.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SYBX|EV/EBITDA Multiple LPCN|Matinas BioPharma Holdings - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SPRB (sprucebiosciences.com)|Enterprise Value to Operating Income Before Depreciation Ratio GLTO (galecto.com)|CTCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LUMO|organovo.com (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Radius Health - Business Value to Operating Income Before Depreciation